201 related articles for article (PubMed ID: 23382304)
21. Molecular and clinical features of K
Hashimoto Y; Dateki S; Hirose M; Satomura K; Sawada H; Mizuno H; Sugihara S; Maruyama K; Urakami T; Sugawara H; Shirai K; Yorifuji T
Pediatr Diabetes; 2017 Nov; 18(7):532-539. PubMed ID: 27681997
[TBL] [Abstract][Full Text] [Related]
22. Infantile spasms as an epileptic feature of DEND syndrome associated with an activating mutation in the potassium adenosine triphosphate (ATP) channel, Kir6.2.
Bahi-Buisson N; Eisermann M; Nivot S; Bellanné-Chantelot C; Dulac O; Bach N; Plouin P; Chiron C; de Lonlay P
J Child Neurol; 2007 Sep; 22(9):1147-50. PubMed ID: 17890419
[TBL] [Abstract][Full Text] [Related]
23. Functional effects of mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), causing neonatal diabetes, and response to sulfonylurea therapy.
Proks P; Girard C; Baevre H; Njølstad PR; Ashcroft FM
Diabetes; 2006 Jun; 55(6):1731-7. PubMed ID: 16731836
[TBL] [Abstract][Full Text] [Related]
24. Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
Bremer AA; Ranadive S; Lustig RH
Pediatr Diabetes; 2008 Jun; 9(3 Pt 1):236-9. PubMed ID: 18221420
[TBL] [Abstract][Full Text] [Related]
25. Successful transfer to sulfonylureas in KCNJ11 neonatal diabetes is determined by the mutation and duration of diabetes.
Babiker T; Vedovato N; Patel K; Thomas N; Finn R; Männikkö R; Chakera AJ; Flanagan SE; Shepherd MH; Ellard S; Ashcroft FM; Hattersley AT
Diabetologia; 2016 Jun; 59(6):1162-6. PubMed ID: 27033559
[TBL] [Abstract][Full Text] [Related]
26. The identification of a R201H mutation in KCNJ11, which encodes Kir6.2, and successful transfer to sustained-release sulphonylurea therapy in a subject with neonatal diabetes: evidence for heterogeneity of beta cell function among carriers of the R201H mutation.
Klupa T; Edghill EL; Nazim J; Sieradzki J; Ellard S; Hattersley AT; Malecki MT
Diabetologia; 2005 May; 48(5):1029-31. PubMed ID: 15838686
[No Abstract] [Full Text] [Related]
27. Detection of KCNJ11 gene mutations in a family with neonatal diabetes mellitus: implications for therapeutic management of family members with long-standing disease.
Abbasi F; Saba S; Ebrahim-Habibi A; Sayahpour FA; Amiri P; Larijani B; Amoli MM
Mol Diagn Ther; 2012 Apr; 16(2):109-14. PubMed ID: 22471336
[TBL] [Abstract][Full Text] [Related]
28. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.
Gloyn AL; Pearson ER; Antcliff JF; Proks P; Bruining GJ; Slingerland AS; Howard N; Srinivasan S; Silva JM; Molnes J; Edghill EL; Frayling TM; Temple IK; Mackay D; Shield JP; Sumnik Z; van Rhijn A; Wales JK; Clark P; Gorman S; Aisenberg J; Ellard S; Njølstad PR; Ashcroft FM; Hattersley AT
N Engl J Med; 2004 Apr; 350(18):1838-49. PubMed ID: 15115830
[TBL] [Abstract][Full Text] [Related]
29. [Neonatal diabetes mellitus].
Huopio H; Otonkoski T
Duodecim; 2011; 127(6):534-41. PubMed ID: 21528518
[TBL] [Abstract][Full Text] [Related]
30. Novel perspectives of super-high dose sulfonylurea and high-dose oral prednisolone in an infant with DEND syndrome due to V64M heterozygote KCNJ11 mutation.
Barash G; Bassan H; Livne A; Benyamini L; Heyman E; Bowman P; Rachmiel M
Acta Diabetol; 2021 Dec; 58(12):1665-1672. PubMed ID: 34272607
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of permanent neonatal diabetes in Slovakia and successful replacement of insulin with sulfonylurea therapy in KCNJ11 and ABCC8 mutation carriers.
Stanik J; Gasperikova D; Paskova M; Barak L; Javorkova J; Jancova E; Ciljakova M; Hlava P; Michalek J; Flanagan SE; Pearson E; Hattersley AT; Ellard S; Klimes I
J Clin Endocrinol Metab; 2007 Apr; 92(4):1276-82. PubMed ID: 17213273
[TBL] [Abstract][Full Text] [Related]
32. Sulphonylurea treatment does not improve psychomotor development in children with KCNJ11 mutations causing permanent neonatal diabetes mellitus accompanied by developmental delay and epilepsy (DEND syndrome).
Sumnik Z; Kolouskova S; Wales JK; Komarek V; Cinek O
Diabet Med; 2007 Oct; 24(10):1176-8. PubMed ID: 17888143
[No Abstract] [Full Text] [Related]
33. Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene.
Slingerland AS; Nuboer R; Hadders-Algra M; Hattersley AT; Bruining GJ
Diabetologia; 2006 Nov; 49(11):2559-63. PubMed ID: 17047922
[TBL] [Abstract][Full Text] [Related]
34. KCNJ11 in-frame 15-bp deletion leading to glibenclamide-responsive neonatal diabetes mellitus in a Chinese child.
Yang W; Wei H; Sang Y
J Pediatr Endocrinol Metab; 2013; 26(7-8):743-6. PubMed ID: 24266052
[TBL] [Abstract][Full Text] [Related]
35. Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences.
Flechtner I; de Lonlay P; Polak M
Diabetes Metab; 2006 Dec; 32(6):569-80. PubMed ID: 17296510
[TBL] [Abstract][Full Text] [Related]
36. Successful transition to sulfonylurea therapy in two Iraqi siblings with neonatal diabetes mellitus and iDEND syndrome due to ABCC8 mutation.
Ozsu E; Giri D; Seymen Karabulut G; Senniappan S
J Pediatr Endocrinol Metab; 2016 Dec; 29(12):1403-1406. PubMed ID: 27849623
[TBL] [Abstract][Full Text] [Related]
37. Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a novel missense mutation, p.P1199L, in the ABCC8 gene.
Oztekin O; Durmaz E; Kalay S; Flanagan SE; Ellard S; Bircan I
J Perinatol; 2012 Aug; 32(8):645-7. PubMed ID: 22842804
[TBL] [Abstract][Full Text] [Related]
38. Transfer from insulin to sulfonylurea treatment in a chinese patient with permanent neonatal diabetes mellitus due to a KCNJ11 R201H mutation.
Xiao X; Wang T; Li W; Song H; Gong C; Diao C; Yu M; Yuan T; Zhang Y; Sun X; Zhang Q; Lu K; Wang H; Schmitz O; Hansen T
Horm Metab Res; 2009 Jul; 41(7):580-2. PubMed ID: 19247925
[No Abstract] [Full Text] [Related]
39. First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
Ioacara S; Flanagan S; Fröhlich-Reiterer E; Goland R; Fica S
J Diabetes Investig; 2017 Sep; 8(5):716-719. PubMed ID: 28083968
[TBL] [Abstract][Full Text] [Related]
40. Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
Mancioppi V; Pozzi E; Zanetta S; Missineo A; Savastio S; Barbetti F; Mellone S; Giordano M; Rabbone I
Front Endocrinol (Lausanne); 2023; 14():1143736. PubMed ID: 37251668
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
